Products for Research Use Only

Avadomide

CAT: 0804-HY-100507-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100507-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2][3].
CAS Number
1015474-32-4
Product Name Alternative
CC 122
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; E1/E2/E3 Enzyme; Molecular Glues; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; NF-κB; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/CC122.html
Purity
99.56
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O
Molecular Formula
C14H14N4O3
Molecular Weight
286.29
Precautions
H302, H315, H319, H335
References & Citations
[1]Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126 (6) :779-89.|[2]Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25 (1) :90-98.|[3]Nishi H, et al., Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2023 Oct;92 (4) :303-314.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2